Floatz logo

phy906

Diarrhea

PhytoCeuticaPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Diarrhea cohort.

Asset / SponsorPhaseRating
Octreotide Pamoate
University of Southern California
Phase 3BB
Irinotecan
Roswell Park Cancer Institute
Phase 3BB
Loperamide
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3BB
L-Ofloxacin
Children's Oncology Group
Phase 3BB
Sulfasalazine
Alliance for Clinical Trials in Oncology
Phase 3BB

View all 25 →

Same molecule, other indications

phy906 is also rated in:

hepatocellular carcinomaDormant
CC
Indicative ·
44 / 100
View asset →
liver cancerDormant
CC
Indicative ·
44 / 100
View asset →
colorectal neoplasmDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →